

Nancy C. Motola, PhD, RAC, Advisor

Former Senior Vice President of
Regulatory & Quality,
Alexion Pharmaceuticals Inc.

Nancy C. Motola, PhD, RAC, has over 30 years' experience in the Pharmaceutical Industry, encompassing both small molecules, biologics, and many therapeutic areas, in regulatory affairs and quality assurance, as well as chemical development/manufacturing. Through her consulting company, Pharma Regulatory Connection, she provides strategic Regulatory expertise for small/start-up, as well as large pharma companies.

Nancy was previously Senior Vice President of Regulatory and Quality for Alexion Pharmaceuticals Inc. and VP Regulatory Affairs for New Haven Pharmaceuticals Inc. In these roles, she was a member of the company's Management Team, built and managed the product compliance organization, and was responsible for the approvals of both company's first products, Soliris, a monoclonal antibody for a rare hematological condition (Alexion), and Durlaza, a controlled release aspirin product for secondary prevention of acute cardiac events (New Haven).

She also served as Senior Vice President of Regulatory Affairs for Rib-X Pharmaceuticals, a development stage anti-infective company. Prior to joining Alexion, Nancy held positions of increasing responsibility in Regulatory Affairs, and achieved approvals of several marketed products at Bayer Corp., Abbott Laboratories, and E.R. Squibb & Sons, Inc., where she also started her career as a process chemist. Nancy received her PhD and MS degrees in Medicinal Chemistry from University of Rhode Island College of Pharmacy; her B.A. degree in chemistry from Central CT. State University; and is Regulatory Affairs Certified (RAC).

She is a member of Connecticut United for Research Excellence (CURE); the Dean's Advisory, GMP Manufacturing Facility and External BS Pharmacy Program Advisory Boards for URI College of Pharmacy; Board of Directors for the Southeastern CT Womens Network (SECTWN); a member of the Scientific Advisory Board of TaiRx (Taiwan); a founder and past chair of the Regulatory Sciences Section of the American Association of Pharmaceutical Scientists (AAPS), a steering committee member of the South Eastern CT Entrepreneurs Network (SECTen); and a frequent contributor to industry programs.